Arsenal Capital Partners, a New York-based private equity firm that invests in middle market industrial, healthcare and financial services companies, has appointed Stephen M. McLean as a partner.
McLean will strengthen Arsenal’s seven-member healthcare practice, help shape the sector investment strategy, and lead the sourcing, evaluation and management of investments.
McLean, a founding partner of Merrill Lynch Capital Partners and its successor funds, has also been an active investor and board member in the healthcare industry for the past 13 years focusing on the areas of life sciences, medical devices and information services.
"Steve has an exceptional track record of investing in, leading, and building companies, and has deep expertise investing in the healthcare sector," says Terrence Mullen, a partner at Arsenal. "We have focused on the healthcare sector since our founding in 2000, have amassed a successful investment track record in the sector, and we are pleased to have someone of Steve’s calibre strengthen our team. Steve’s extensive industry network and domain knowledge align with the Arsenal strategy and model and his complementary expertise will further augment our healthcare effort. Steve is a terrific person and team player who fits well with the culture of our organisation."
McLean’s healthcare experience includes having been a founding investor and director of Agencourt Bioscience and Agencourt Personal Genomics. He was also an investor and member of the board of Packard Bioscience, among other companies.
He currently serves on the boards of several healthcare companies including Avantra Bioscience, RS Medical, and CentriHealth. In addition, McLean is chairman of the International Biomedical Research Alliance, a private sector foundation formed to support an advanced biomedical PhD programme in conjunction with the National Institutes of Health, Oxford University and Cambridge University.
